Sentinel node mapping for breast cancer: progress to date and prospects for the future

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Sentinel node biopsy (SNB) is currently indicated for early-stage invasive breast cancer with clinically negative lymph nodes.
• Expanding SNB applications to larger tumors, ductal carcinoma in situ, and suspicious nodes is under investigation.
• SNB offers a less invasive alternative to axillary lymph node dissection (ALND), with fewer and less severe complications.

Purpose of the Study:

• To review the current indications and expanding role of SNB in breast cancer management.
• To discuss the ongoing research and future directions for SNB implementation.
• To highlight SNB's established position as the standard of care for early breast cancer.

Main Methods:

• Review of current clinical practice guidelines for SNB.
• Analysis of recent studies and clinical trials (e.g., NSABP B-32, ACOSOG Z10, Z11).
• Discussion of the comparative safety and efficacy of SNB versus ALND.

Main Results:

• SNB is increasingly utilized beyond its initial indications.
• Further research is needed to determine optimal SNB timing with neoadjuvant chemotherapy.
• Evidence supports SNB as a safer alternative to ALND.

Conclusions:

• Sentinel node biopsy has become the standard of care for early breast cancer treatment.
• Ongoing research aims to further refine SNB indications and protocols.
• The trend is towards broader application of SNB due to its favorable safety profile.